# ArthroSave

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arthrosave-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Culemborg, Netherlands
- Website: www.arthrosave.com
- Latest round: Series A (Dec 29, 2018)
- Investors on record: 3

## About

Based in the Netherlands, ArthroSave B.V. specializes in the development of innovative medical devices for treating knee osteoarthritis, notably through their flagship product, the KneeReviver.ArthroSave B.V. is focused on creating medical devices that aid in knee osteoarthritis treatment. Founded in Culemborg, Netherlands in 2016, the company has completed a total of 2 deals. The latest funding round occurred on January 5, 2023, raising EUR 2.6 million led by Oost NL, with participation from Essential Investments. The total amount raised by the company is EUR 2.6 million.ArthroSave focuses on the development and provision of innovative medical devices aimed at treating knee osteoarthritis, particularly through their flagship product, the KneeReviver. This device is designed to unload the damaged knee joint by creating space between the joint surfaces, allowing for the regeneration of knee joint tissues. The treatment protocol for patients involves a six-week period during which the KneeReviver is applied, targeting individuals under 65 years of age who have not responded to conservative therapies and are possibly facing knee replacement surgery. The company collaborates with orthopaedic surgeons, researchers, and patients to refine and enhance the effectiveness of the KneeReviver, which has been extensively studied for over a decade. Currently, the product is offered in various international markets, including The Netherlands and Switzerland, catering primarily to patients diagnosed with knee osteoarthritis.ArthroSave generates revenue through the sale of the KneeReviver, primarily targeting healthcare institutions and professionals who provide knee osteoarthritis treatments. The company employs a direct-to-consumer model, which includes partnerships with hospitals and clinics that administer the KneeReviver as part of their treatment options. The revenue model may also incorporate service agreements or contracts for ongoing support and maintenance of the device, ensuring that healthcare providers can effectively utilize the technology in their practices. Specific pricing structures for the KneeReviver and associated services are established through negotiated agreements, aligning with the healthcare providers' operational frameworks and patient care strategies.In January 2023, ArthroSave B.V. raised EUR 2.6 million in venture funding led by new investor Oost NL, with participation from another new investor Essential Investments. The company will utilize the funding to initiate clinical trials and expand the market for the KneeReviver. Future plans include developing new products targeted at enhancing knee treatment options and exploring expansion into additional international markets.

## Funding rounds

- Series A, Dec 29, 2018 — Oost NL, MSB-Isala, Weskiway BV

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series A
- MSB-Isala — Series A
- Weskiway BV — Series A